TP53 and cervical squamous intraepithelial neoplasia: These molecular signatures collectively differentiate EOCRC from late-onset disease, highlighting both unique vulnerabilities (e.g., higher TP53 mutation burden, CIN-driven aggressiveness) and potential therapeutic opportunities, such as immunotherapy for MSI-H tumors and pathway-targeted interventions for CIN-driven cancers [60,61,62].